9 Biotech Valuation Killers (Ep. 3 of The Pharmcast)

November 17, 2016 Jim Combs

 

This week in the Pharmcast, we discuss "9 Biotech Valuation Killers" with Dr. Brian Daniels, the former SVP of Global Development for Bristol-Myers Squibb and now Venture Partner with 5AM Ventures, and Dr. Don Therasse, former VP of Global Patient Safety and Medical Affairs for Eli Lilly & Company.  

According to a global study by Mergermarket and Reed Smith, 94 percent of senior life sciences executives plan to make an acquisition in 2016, so biotech firms need to do everything possible to make sure they are properly positioned.

These gentlemen have evaluated hundreds of assets throughout their careers, so we asked them to share their best advice to biotechs looking to attract big pharma suitors and at maximum valuations.

The first rule is to have good science. This is a given. After that, follow nine rules to maximize valuations, which Drs. Daniels and Therasse present in episode 3 of The Pharmcast.

Listen to more Pharmcast episodes about Medtech Valuation Killers here!

The Pharmcast is now available for download on iTunes, Google Play, and Stitcher. If you like what you hear, share it with your friends and write a review. 

Previous Article
Billion Dollar Bets: Lessons on Innovation from a BMS Chief Scientific Officer, Dr. Elliott Sigal (Ep. 4 on The Pharmcast)
Billion Dollar Bets: Lessons on Innovation from a BMS Chief Scientific Officer, Dr. Elliott Sigal (Ep. 4 on The Pharmcast)

  Each week in The Pharmcast, we talk with top industry experts from our network or beyond ab...

Next Article
Leading the Bristol-Myers Squibb Transformation (Part 2) (Ep. 2 of The Pharmcast)
Leading the Bristol-Myers Squibb Transformation (Part 2) (Ep. 2 of The Pharmcast)

  A continuation of our maiden voyage of the Pharmcast, we talk with a trio of former Bristol...